These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 22326504)

  • 1. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).
    Andress DL; Coll B; Pritchett Y; Brennan J; Molitch M; Kohan DE
    Life Sci; 2012 Oct; 91(13-14):739-42. PubMed ID: 22326504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy.
    Kohan DE; Pritchett Y; Molitch M; Wen S; Garimella T; Audhya P; Andress DL
    J Am Soc Nephrol; 2011 Apr; 22(4):763-72. PubMed ID: 21372210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
    Heerspink HJL; Andress DL; Bakris G; Brennan JJ; Correa-Rotter R; Dey J; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray J; Perkovic V; Tobe S; Wigderson M; Parving HH; de Zeeuw D
    Diabetes Obes Metab; 2018 Jun; 20(6):1369-1376. PubMed ID: 29405626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
    Heerspink HJL; Parving HH; Andress DL; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Melnick JZ; Miller MG; Pergola PE; Perkovic V; Tobe S; Yi T; Wigderson M; de Zeeuw D;
    Lancet; 2019 May; 393(10184):1937-1947. PubMed ID: 30995972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
    Heerspink HJL; Xie D; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Perkovic V; Rossing P; Parving HH; de Zeeuw D;
    J Am Soc Nephrol; 2021 Nov; 32(11):2900-2911. PubMed ID: 34551995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.
    de Zeeuw D; Coll B; Andress D; Brennan JJ; Tang H; Houser M; Correa-Rotter R; Kohan D; Lambers Heerspink HJ; Makino H; Perkovic V; Pritchett Y; Remuzzi G; Tobe SW; Toto R; Viberti G; Parving HH
    J Am Soc Nephrol; 2014 May; 25(5):1083-93. PubMed ID: 24722445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A
    Waijer SW; Gansevoort RT; Bakris GL; Correa-Rotter R; Hou FF; Kohan DE; Kitzman DW; Makino H; McMurray JJV; Perkovic V; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL
    Clin J Am Soc Nephrol; 2021 Dec; 16(12):1824-1832. PubMed ID: 34853062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Webb DJ; Coll B; Heerspink HJL; Andress D; Pritchett Y; Brennan JJ; Houser M; Correa-Rotter R; Kohan D; Makino H; Perkovic V; Remuzzi G; Tobe SW; Toto R; Busch R; Pergola P; Parving HH; de Zeeuw D
    Drugs R D; 2017 Sep; 17(3):441-448. PubMed ID: 28831752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline characteristics and enrichment results from the SONAR trial.
    Heerspink HJL; Andress DL; Bakris G; Brennan JJ; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray J; Perkovic V; Tobe S; Wigderson M; Yi T; Parving HH; de Zeeuw D
    Diabetes Obes Metab; 2018 Aug; 20(8):1829-1835. PubMed ID: 29604160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy.
    Kohan DE; Lambers Heerspink HJ; Coll B; Andress D; Brennan JJ; Kitzman DW; Correa-Rotter R; Makino H; Perkovic V; Hou FF; Remuzzi G; Tobe SW; Toto R; Parving HH; de Zeeuw D
    Clin J Am Soc Nephrol; 2015 Sep; 10(9):1568-74. PubMed ID: 26153128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight.
    Koomen JV; Stevens J; Mostafa NM; Parving HH; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2018 Aug; 20(8):2019-2022. PubMed ID: 29603851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy.
    Pena MJ; de Zeeuw D; Andress D; Brennan JJ; Correa-Rotter R; Coll B; Kohan DE; Makino H; Perkovic V; Remuzzi G; Tobe SW; Toto R; Parving HH; Sharma S; Corringham T; Sharma K; Heerspink HJL
    Diabetes Obes Metab; 2017 May; 19(5):749-753. PubMed ID: 28019071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
    Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
    JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.
    Katayama S; Yamada D; Nakayama M; Yamada T; Myoishi M; Kato M; Nowack C; Kolkhof P; Yamasaki Y;
    J Diabetes Complications; 2017 Apr; 31(4):758-765. PubMed ID: 28025025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers.
    Schievink B; de Zeeuw D; Smink PA; Andress D; Brennan JJ; Coll B; Correa-Rotter R; Hou FF; Kohan D; Kitzman DW; Makino H; Parving HH; Perkovic V; Remuzzi G; Tobe S; Toto R; Hoekman J; Lambers Heerspink HJ
    Eur J Prev Cardiol; 2016 May; 23(7):758-68. PubMed ID: 26229089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial.
    Koomen JV; Stevens J; Bakris G; Correa-Rotter R; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray JJV; Parving HH; Perkovic V; Tobe SW; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2021 Feb; 23(2):561-568. PubMed ID: 33184931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease.
    Smeijer JD; Kohan DE; Rossing P; Correa-Rotter R; Liew A; Tang SCW; de Zeeuw D; Gansevoort RT; Ju W; Lambers Heerspink HJ
    Cardiovasc Diabetol; 2023 Sep; 22(1):251. PubMed ID: 37716952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.